TCGA-GD-A3OS-01A-12R-A220-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.95926413
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- MITOTIC_SPINDLE+0.280
- G2M_CHECKPOINT+0.250
- E2F_TARGETS+0.190
- MYOGENESIS+0.190
- DNA_REPAIR+0.160
- KRAS_SIGNALING_DN+0.160
- WNT_BETA_CATENIN_SIGNALING+0.160
- MYC_TARGETS_V2+0.150
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.370
- ESTROGEN_RESPONSE_LATE-0.350
- P53_PATHWAY-0.340
- INFLAMMATORY_RESPONSE-0.330
- ADIPOGENESIS-0.320
- CHOLESTEROL_HOMEOSTASIS-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
- INTERFERON_GAMMA_RESPONSE-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- XENOBIOTIC_METABOLISM-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088886 | — | — | 0.845 |
| 2 | 20100144.Her2HRpos | — | D | 0.843 |
| 3 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.839 |
| 4 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.832 |
| 5 | 20130253.TNBC | — | E | 0.831 |
| 6 | SRR8518210 | — | E | 0.831 |
| 7 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.827 |
| 8 | SRR6013547 | — | cohortMD1 | 0.826 |
| 9 | SRR4296090 | — | cohortMD1 | 0.825 |
| 10 | SRR5088885 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.070 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.040 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |